Details of the Drug

General Information of Drug (ID: DMTL94F)

Drug Name
Maraviroc
Synonyms
376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Chronic obstructive pulmonary disease CA22 Phase 3 [1]
Therapeutic Class
Anti-HIV Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 513.7
Logarithm of the Partition Coefficient (xlogp) 5.1
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
The bioavailability of drug is 23% []
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.4 mL/min/kg [3]
Elimination
8% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 14 - 18 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 33.373 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.25% [3]
Vd
The volume of distribution (Vd) of drug is 194 L []
Chemical Identifiers
Formula
C29H41F2N5O
IUPAC Name
4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
Canonical SMILES
CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
InChI
InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
InChIKey
GSNHKUDZZFZSJB-HLMSNRGBSA-N
Cross-matching ID
PubChem CID
3002977
ChEBI ID
CHEBI:63608
CAS Number
376348-65-1
DrugBank ID
DB04835
TTD ID
D0NR6S
VARIDT ID
DR00730
ACDINA ID
D00384
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 5 (CCR5) TT2CEJG CCR5_HUMAN Antagonist [5]
CCR5 messenger RNA (CCR5 mRNA) TTJIH8Q CCR5_HUMAN Antagonist [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Lung tissue
The Studied Disease Chronic obstructive pulmonary disease [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-C chemokine receptor type 5 (CCR5) DTT CCR5 5.10E-01 0.03 0.05
C-C chemokine receptor type 5 (CCR5) DTT CCR5 5.43E-01 1.04E-02 0.02
P-glycoprotein 1 (ABCB1) DTP P-GP 1.24E-01 -4.12E-01 -4.68E-01
P-glycoprotein 1 (ABCB1) DTP P-GP 3.00E-02 -1.09E-02 -7.37E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Maraviroc
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Cobicistat DM6L4H2 Moderate Decreased metabolism of Maraviroc caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [8]
Etravirine DMGV8QU Moderate Increased metabolism of Maraviroc caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [8]
Coadministration of a Drug Treating the Disease Different from Maraviroc (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [9]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Maraviroc caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [8]
Midostaurin DMI6E0R Moderate Decreased metabolism of Maraviroc caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [9]
Arn-509 DMT81LZ Major Increased metabolism of Maraviroc caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [9]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [9]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Maraviroc caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [9]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Maraviroc and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [10]
Troleandomycin DMUZNIG Major Decreased metabolism of Maraviroc caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [9]
Erdafitinib DMI782S Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [11]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Maraviroc and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [12]
HKI-272 DM6QOVN Moderate Decreased clearance of Maraviroc due to the transporter inhibition by HKI-272. Breast cancer [2C60-2C6Y] [9]
Tucatinib DMBESUA Major Decreased metabolism of Maraviroc caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [9]
Palbociclib DMD7L94 Moderate Decreased metabolism of Maraviroc caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [9]
Alpelisib DMEXMYK Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [9]
PF-04449913 DMSB068 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [9]
Ulipristal DMBNI20 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Ulipristal. Contraceptive management [QA21] [9]
Lumacaftor DMCLWDJ Major Increased metabolism of Maraviroc caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [9]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Maraviroc caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [9]
MK-8228 DMOB58Q Moderate Decreased clearance of Maraviroc due to the transporter inhibition by MK-8228. Cytomegaloviral disease [1D82] [9]
Cenobamate DM8KLU9 Moderate Increased metabolism of Maraviroc caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [8]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Maraviroc caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [8]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Maraviroc and Cannabidiol. Epileptic encephalopathy [8A62] [13]
Tazemetostat DMWP1BH Moderate Increased metabolism of Maraviroc caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [8]
Boceprevir DMBSHMF Major Decreased metabolism of Maraviroc caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [9]
Telaprevir DMMRV29 Major Decreased metabolism of Maraviroc caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [9]
Daclatasvir DMSFK9V Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [9]
GS-5885 DMSL3DX Moderate Decreased clearance of Maraviroc due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [9]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Maraviroc and Brentuximab vedotin. Hodgkin lymphoma [2B30] [14]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Maraviroc and Mipomersen. Hyper-lipoproteinaemia [5C80] [15]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Maraviroc and Teriflunomide. Hyper-lipoproteinaemia [5C80] [16]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Maraviroc and BMS-201038. Hyper-lipoproteinaemia [5C80] [17]
Tolvaptan DMIWFRL Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [9]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Maraviroc caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [9]
Suvorexant DM0E6S3 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Suvorexant. Insomnia [7A00-7A0Z] [9]
Crizotinib DM4F29C Moderate Decreased metabolism of Maraviroc caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [9]
Brigatinib DM7W94S Moderate Increased metabolism of Maraviroc caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [18]
Ceritinib DMB920Z Major Decreased metabolism of Maraviroc caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [9]
PF-06463922 DMKM7EW Moderate Accelerated clearance of Maraviroc due to the transporter induction by PF-06463922. Lung cancer [2C25] [8]
Capmatinib DMYCXKL Moderate Decreased metabolism of Maraviroc caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [9]
Selpercatinib DMZR15V Moderate Decreased metabolism of Maraviroc caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [9]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Maraviroc and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [19]
Idelalisib DM602WT Major Decreased metabolism of Maraviroc caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [9]
Ibrutinib DMHZCPO Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Ibrutinib. Mature B-cell lymphoma [2A85] [13]
Ponatinib DMYGJQO Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [9]
Vemurafenib DM62UG5 Moderate Increased metabolism of Maraviroc caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [8]
Lasmiditan DMXLVDT Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Lasmiditan. Migraine [8A80] [20]
Flibanserin DM70DTN Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Flibanserin. Mood disorder [6A60-6E23] [9]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Maraviroc and Ozanimod. Multiple sclerosis [8A40] [21]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Maraviroc caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [9]
Nilotinib DM7HXWT Moderate Decreased metabolism of Maraviroc caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [9]
Rolapitant DM8XP26 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [22]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Maraviroc caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [9]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Maraviroc and Safinamide. Parkinsonism [8A00] [21]
Istradefylline DM20VSK Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Istradefylline. Parkinsonism [8A00] [9]
Abametapir DM2RX0I Moderate Decreased metabolism of Maraviroc caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [23]
Lefamulin DME6G97 Moderate Decreased metabolism of Maraviroc caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [24]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Maraviroc caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [9]
Enzalutamide DMGL19D Major Increased metabolism of Maraviroc caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [9]
Voxelotor DMCS6M5 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Voxelotor. Sickle-cell disorder [3A51] [9]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Maraviroc caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [13]
Larotrectinib DM26CQR Moderate Decreased metabolism of Maraviroc caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [9]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Maraviroc and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [13]
Armodafinil DMGB035 Moderate Increased metabolism of Maraviroc caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
LEE011 DMMX75K Moderate Decreased metabolism of Maraviroc caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [9]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Maraviroc caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [25]
Brilinta DMBR01X Moderate Decreased metabolism of Maraviroc caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [9]
Cabozantinib DMIYDT4 Moderate Decreased clearance of Maraviroc due to the transporter inhibition by Cabozantinib. Thyroid cancer [2D10] [9]
Elagolix DMB2C0E Moderate Increased metabolism of Maraviroc caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [8]
⏷ Show the Full List of 68 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Calcium hydrogenphosphate E00294 24441 Diluent
Magnesium stearate E00208 11177 lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Maraviroc 150 mg tablet 150 mg Oral Tablet Oral
Maraviroc 25 mg tablet 25 mg Oral Tablet Oral
Maraviroc 300 mg tablet 300 mg Oral Tablet Oral
Maraviroc 75 mg tablet 75 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 806).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9.
6 Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72.
7 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
8 Cerner Multum, Inc. "Australian Product Information.".
9 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
10 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
11 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
12 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
13 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
14 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
15 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
16 Canadian Pharmacists Association.
17 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
18 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
19 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
20 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
21 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
22 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
23 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
24 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
25 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.